Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
Peter Connick(University of Cambridge), Siddharthan Chandran(Edinburgh Royal Infirmary), Madhan Kolappan(University College London), Alan J. Thompson(Queen Mary University of London), Daniel J. Webber(University of Cambridge), Rickie Patani(National Hospital for Neurology and Neurosurgery), Alastair Compston(University of Cambridge), Shi‐Lu Luan(University of Cambridge), David H. Miller(National Hospital for Neurology and Neurosurgery), Andrew W. Michell(University of Cambridge), Daniel R. Altmann(London School of Hygiene & Tropical Medicine), Ming‐Qing Du(MRC Laboratory of Molecular Biology), Charles Crawley(Addenbrooke's Hospital), Michael A. Scott(Michigan State University)
Cited by 606
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k